---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-056953"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-08-14T12:40:50+00:00"
generated_at: "2026-08-14T12:45:09.016494+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vistagen Q1 FY27 net loss $13.0M; cash $31.7M; FDA meeting planned for fasedienol path

## Summary
- Net loss $13.0M for Q1 ended June 30, 2026, vs $15.1M year-ago; revenue $1.2M from Fuji Pharma exclusivity expiration.
- Cash, equivalents and marketable securities $31.7M; sufficient into 2027 but not beyond one year from now.
- PALISADE-4 missed primary endpoint overall; post-hoc very severe SAD subpopulation showed nominally significant improvement vs placebo.
- FDA meeting planned this quarter to discuss potential Phase 3 registrational path for fasedienol in social anxiety disorder.
- Appointed Angel S. Angelov, M.D., MBA as CMO and Douglas J. Williamson, M.D. to Board; FDA 'Study May Proceed' for refisolone.

## SEC filing metadata
- accession: 0001628280-26-056953
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-08-14T12:40:50+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026056953/0001628280-26-056953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026056953/vtgn-20260814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-056953
- JSON: https://secwatch.observer/filing/0001628280-26-056953.json
- Plain text: https://secwatch.observer/filing/0001628280-26-056953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.